Drug Trial Radar · NCT00660894
Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery
Last checked: Nov 19, 2026Latest source record: Aug 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,535
Actual
Start
Apr 2008
Primary completion
Jun 2012
Study completion Jul 2015
Sponsor
- Lead sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 17, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy, such as tegafur-uracil, leucovorin, and S-1, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving tegafur-uracil together with leucovorin is more effective than giving S-1 in treating patients with stage III colon cancer. PURPOSE: This randomized phase III trial is studying giving tegafur-uracil together with leucovorin to see how well it works compared with giving S-1 in treating patients with stage III colon cancer that has been completely removed by surgery.
Conditions
- Colorectal Cancer
Interventions
folinate calciumDrug
tegafur-uracilDrug
tegafur-gimeracil-oteracil potassiumDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-free survival
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tokyo Medical and Dental University
Tokyo, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.